HUP0104579A2 - GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása - Google Patents
GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazásaInfo
- Publication number
- HUP0104579A2 HUP0104579A2 HU0104579A HUP0104579A HUP0104579A2 HU P0104579 A2 HUP0104579 A2 HU P0104579A2 HU 0104579 A HU0104579 A HU 0104579A HU P0104579 A HUP0104579 A HU P0104579A HU P0104579 A2 HUP0104579 A2 HU P0104579A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- glp
- analogues
- pharmaceutical compositions
- group
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000962 organic group Chemical group 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
Abstract
A tal lm ny szerinti vegyületek (I) ltal nos képletében A7-A37jelentése egym stól függetlenül aminosavakból sz rmaztatott csoportokk"zül v lasztott csoport, R1 jelentése hidroxil-, amino- vagyalkoxicsoport vagy szerves csoport, R2 és R3 jelentése egym stólfüggetlenül hidrogénatom vagy szerves csoport. A tal lm ny trgyk"réhez tartoznak tov bb a fenti vegyületeket tartalmazó gyógyszati készítmények, valamint evegyületek alkalmaz sa. A tal lm nyszerinti vegyületek alkalmasak GLP-1 receptorból agonista hat s kiv lts ra. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11118698P | 1998-12-07 | 1998-12-07 | |
US20683398A | 1998-12-07 | 1998-12-07 | |
PCT/US1999/028929 WO2000034332A1 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104579A2 true HUP0104579A2 (hu) | 2002-04-29 |
HUP0104579A3 HUP0104579A3 (en) | 2002-05-28 |
Family
ID=26808707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104579A HUP0104579A3 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues, pharmaceutical compositions comprising thereof and their use |
Country Status (21)
Country | Link |
---|---|
US (2) | US7368427B1 (hu) |
EP (2) | EP1137666B9 (hu) |
JP (3) | JP2002538081A (hu) |
KR (1) | KR100458748B1 (hu) |
CN (2) | CN100334109C (hu) |
AT (1) | ATE394423T1 (hu) |
AU (1) | AU770609B2 (hu) |
BR (1) | BR9916027A (hu) |
CA (1) | CA2352573C (hu) |
CZ (2) | CZ303120B6 (hu) |
DE (1) | DE69938669D1 (hu) |
DK (1) | DK1137666T5 (hu) |
ES (1) | ES2302390T3 (hu) |
HU (1) | HUP0104579A3 (hu) |
IL (2) | IL143481A0 (hu) |
NO (2) | NO330293B1 (hu) |
PL (3) | PL393611A1 (hu) |
PT (1) | PT1137666E (hu) |
RU (1) | RU2208015C2 (hu) |
TW (2) | TWI339208B (hu) |
WO (1) | WO2000034332A1 (hu) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ295768B6 (cs) | 1998-12-07 | 2005-10-12 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující |
DK1137666T5 (da) * | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
EP1305338A2 (en) * | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modified peptides with increased potency |
EP1970072A1 (en) | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
NZ519752A (en) | 2000-10-20 | 2005-04-29 | Amylin Pharmaceuticals Inc | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
CA2430934C (en) | 2000-12-01 | 2011-06-21 | Takeda Chemical Industries, Ltd. | A method of producing sustained-release preparations of a bioactive substance using high-pressure gas |
AU2012202081B2 (en) * | 2001-07-31 | 2014-09-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
DE60228972D1 (de) * | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
RU2353625C2 (ru) * | 2001-10-18 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний |
PL212106B1 (pl) * | 2002-07-23 | 2012-08-31 | Sod Conseils Rech Applic | Analogi greliny, ich zastosowanie oraz sposób identyfikacji związku zdolnego do wiązania się z receptorem GHS |
EP2277527A3 (en) * | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Peptide YY analogs |
JP2007524579A (ja) * | 2003-02-19 | 2007-08-30 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1の類似体 |
US7847063B2 (en) * | 2003-03-28 | 2010-12-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | GLP-1 derivative |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
WO2005058955A1 (en) * | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of glp-1 |
JP2007514752A (ja) * | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1医薬組成物 |
AU2005203925A1 (en) * | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-Like Peptide-1 analogs with long duration of action |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
WO2006134340A2 (en) * | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
MX2008013304A (es) | 2006-04-20 | 2008-10-27 | Amgen Inc | Compuestos de peptido 1 tipo glucagon. |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
WO2008086086A2 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
WO2009035540A2 (en) * | 2007-09-07 | 2009-03-19 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
US8450270B2 (en) * | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
WO2010076809A2 (en) * | 2008-12-29 | 2010-07-08 | Panacea Biotec Ltd | Glp-1 analogs and uses thereof |
RU2580317C2 (ru) * | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
CN102584982B (zh) * | 2012-02-10 | 2014-02-05 | 深圳翰宇药业股份有限公司 | 一种纯化固相合成利拉鲁肽粗肽的方法 |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
AU2014272500B2 (en) | 2013-05-28 | 2018-03-08 | Scohia Pharma, Inc. | Peptide compound |
CN103285379A (zh) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途 |
AU2014278183B2 (en) | 2013-06-11 | 2018-10-04 | Receptos Llc | Novel GLP-1 receptor modulators |
AU2015292356B2 (en) | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
EP3230276B1 (en) | 2014-12-10 | 2020-09-02 | Celgene International II Sarl | Glp-1 receptor modulators |
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
ES2968038T3 (es) | 2015-12-23 | 2024-05-06 | Univ Johns Hopkins | Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas |
WO2017112824A2 (en) | 2015-12-23 | 2017-06-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
WO2017210241A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble & chemically stable glucagon peptides |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
CN109942696A (zh) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | 长效化胰高血糖素样肽-1(glp-1)类似物及其应用 |
CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1539498A (en) | 1925-05-26 | And fifteen | ||
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO1991011457A1 (en) * | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
EP0646128A1 (en) * | 1992-06-15 | 1995-04-05 | Scios Inc. | Glucagon-like peptide and insulinotropin derivatives |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
AU2263197A (en) * | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
JP3149958B2 (ja) * | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
AU6586298A (en) * | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
AU2610599A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
DK1137666T5 (da) | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
CZ295768B6 (cs) | 1998-12-07 | 2005-10-12 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující |
EP1239871A1 (en) | 1999-11-12 | 2002-09-18 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
-
1999
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active IP Right Cessation
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en active Application Filing
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
-
2000
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
-
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
-
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
-
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
-
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
-
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104579A2 (hu) | GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása | |
HUP0103283A2 (hu) | Proteázokat gátló pirazinonszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
DE69520880D1 (de) | 9-deoxotaxan verbindungen | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0102453A2 (hu) | Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények | |
HUP0105154A2 (hu) | Cluster típusú fejfájás kezelésére alkalmas görcsoldószármazékok | |
IL108520A0 (en) | Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them | |
BR9707064A (pt) | Novos derivados 19-nor-pregneno | |
FR2712591B1 (fr) | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. | |
HUP0001164A2 (hu) | PF1022-ciklodepszipeptid-származékok | |
MY117852A (en) | Alkylaminobenzothiazole and- benzoxazole derivatives | |
HUP0002683A2 (hu) | Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek | |
HUP0102903A2 (hu) | Nokatiacin antibiotikumok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0105280A2 (hu) | Benzaldehidszármazékok és gyógyászati alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0104963A2 (hu) | Bőrbetegségek kezelésére szolgáló készítmények | |
HUP0103751A2 (hu) | Epesavval helyettesített fenilalkenoilguanidinek, valamint e vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására | |
HUT53664A (en) | Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
HUP0103303A2 (hu) | Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
ES8606880A1 (es) | Un procedimiento para la preparacion de nuevos peptidos. | |
GR3031820T3 (en) | 4-amino-n --(4-methyl-4-piperidinyl)-2-methoxybenzamides. | |
HUP0101715A2 (hu) | Eljárások és készítmények reumatoid artritisz kezelésére | |
HUP0105037A2 (hu) | Traumás stressz utáni elváltozások kezelésére alkalmas antikonvulzáns hatású származékok | |
HUP0300066A2 (hu) | Polipeptid vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények | |
HUP0100283A2 (hu) | Új triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: IPSEN PHARMA S.A.S., FR Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS, FR Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL F, US Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS, FR |
|
FD9A | Lapse of provisional protection due to non-payment of fees |